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ABSTRACT
RNA-binding proteins (RBPs) are increasingly iden-
tified as post-transcriptional drivers of cancer pro-
gression. The RBP LARP1 is an mRNA stability regu-
lator, and elevated expression of the protein in hepa-
tocellular and lung cancers is correlated with adverse
prognosis. LARP1 associates with an mRNA inter-
actome that is enriched for oncogenic transcripts.
Here we explore the role of LARP1 in epithelial ovar-
ian cancer, a disease characterized by the rapid ac-
quisition of resistance to chemotherapy through the
induction of pro-survival signalling. We show, using
ovarian cell lines and xenografts, that LARP1 is re-
quired for cancer cell survival and chemotherapy re-
sistance. LARP1 promotes tumour formation in vivo
and maintains cancer stem cell-like populations. Us-
ing transcriptomic analysis following LARP1 knock-
down, cross-referenced against the LARP1 interac-
tome, we identify BCL2 and BIK as LARP1 mRNA
targets. We demonstrate that, through an interaction
with the 3′ untranslated regions (3′ UTRs) of BCL2
and BIK, LARP1 stabilizes BCL2 but destabilizes BIK
with the net effect of resisting apoptosis. Together,
our data indicate that by differentially regulating the
stability of a selection of mRNAs, LARP1 promotes
ovarian cancer progression and chemotherapy resis-
tance.
INTRODUCTION
Improvements to RNA capture and sequencing methods
have highlighted RNA binding proteins (RBPs) as impor-
tant post-transcriptional contributors to gene expression
and cellular behaviour. In normal cells, mRNAs have pre-
determined half-lives; the most short-lived transcripts be-
ing enriched for proto-oncogenic functions such as cell cy-
cle progression and evasion of apoptosis, and those with the
longest lifespans encoding housekeeping genes (1–4). There
is accumulating evidence that RBPs such as the 5′ cap com-
plex protein eIF4E contribute to human diseases including
cancer (1,5) by selectively binding and altering the half-lives
ofmRNA transcripts involved in pathological processes (6).
La-Related Protein 1 (LARP1) is a highly evolutionarily-
conserved RBP and member of the LARP family, each car-
rying a conserved La domain, an RNA-binding region that
was originally identified in La protein (or LARP3/genuine
La/SSB (7–11)). LARP1 is unique amongst the LARPs
in possessing an additional conserved C-terminal tandem-
repeat motif, termed the DM15 region. The crystal struc-
ture of this motif has recently been characterized, and iden-
tified as a putative mRNA-binding domain (12). LARP1 is
a regulator of both mRNA stability and translation (11,13–
15), and has recently been shown to bind RAPTOR, act
within themTORC1 signalling cascade and regulate 5′ TOP
stability (16,17). LARP1 protein is highly expressed in hep-
atocellular and lung cancers, where it is an independent pre-
dictor of adverse prognosis (18). We have shown previously
that expression of LARP1 is elevated in squamous cervi-
cal cancer, that LARP1 promotes cell motility and invasion,
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and is complexed with an mRNA interactome enriched for
oncogenic transcripts (15).
Here we explore the role of LARP1 in epithelial ovar-
ian cancer (EOC), a disease responsible for over 140 000
deaths worldwide every year (19). EOC is the most lethal
of gynaecological malignancies, with the development of
recurrent, increasingly chemotherapy-resistant disease ac-
counting for its high mortality (20,21). Recently, it has been
proposed that transformed stem cells may be the origin of
some subtypes of EOC and that cancer stem cells are in-
nately chemotherapy resistant (22,23). Here we interrogate
the LARP1 interactome in the context of ovarian cancer to
characterize the interactions between LARP1 and its tar-
get genes and observe the impact of these interactions on
stem cell marker expression, chemotherapy resistance and
patient survival outcome. Our findings identify LARP1 as
a key post-transcriptional regulator of ovarian cancer be-
haviour.
MATERIALS AND METHODS
Cell culture and drug treatment
OVCAR8, HeLa, PEO1, PEO4, IGROV1 and OVCAR4
cells were kindly provided by the Ovarian Cancer Action
Biobank at Imperial College, and were genotyped prior to
use. SKOV3 and OVCAR3 cells were obtained fromATCC.
OVCAR3 cells were cultured in RPMI supplemented with
20% foetal calf serum (FCS) and 0.01 mg/ml bovine insulin
(Sigma-Aldritch). All other lines were cultured in RPMI
with 10% FCS, with the exception of HeLa cells, which
were maintained in Dulbecco’s modified Eagle’s medium.
All media was supplemented with L-glutamine (Gibco) to
a final concentration of 2 mM. All lines were cultured at
37◦C in 5% CO2. For drug treatments, cells were exposed to
cisplatin (Accord Healthcare), gemcitabine (Hospira) and
paclitaxel (TEVA UK) at the stated concentrations. Salino-
mycin (Sigma-Aldritch) was resuspended in dimethyl sul-
foxide (DMSO) and added to culture medium.
mRNA-sequencing and data analysis
Total RNA from three biological repeats was extracted
from OVCAR8 cells following transient LARP1 knock-
down with the miRNeasy kit (Qiagen) following the man-
ufacturer’s instructions, with on-column DNAse digestion
(QIAGEN). Polyadenylated RNA was enriched using the
Dynabead mRNA-purification kit and fragmented using
the Ambion fragmentation reagent (both Life Technolo-
gies). First-strand cDNA was generated using random
hexamer-primed reverse transcription, with First Strand
Master Mix and the SuperScript II Reverse Transcriptase
kit (Invitrogen), with dUTP used during second-strand syn-
thesis. The resulting cDNA was purified with Agencourt
AMPure XP Beads (Beckman Coulter) then end-repaired
and 3′ adenylated and adaptors were ligated. Products were
separated by agarose gel electrophoresis, and fragments be-
tween 300 and 350 bp were excised and eluted. Uracil-N-
Glycosylase (UNG, Applied Biosystems) was used to de-
grade the second-strand cDNA, and products were ampli-
fied and re-purified. Library quantification and quality con-
trol was performed using the Agilent 2100 Bio-analyzer and
the ABI StepOnePlus Real-Time PCR System.
Paired-end 100 bp sequencing was performed using
the Illumina HiSeq2000 platform at Beijing Genomics
Institute, Shenzhen. Following quality control, clean
reads were aligned to Hg19 reference sequences using
SOAPaligner/SOAP2 (24), allowing for up to five mis-
matches. Gene expression was determined using the reads
per kilobase per million reads (RPKM) method (25),
and the ratio between siCONTROL and siLARP1 sam-
ples calculated. Functional enrichment analysis was con-
ducted with Ingenuity Pathway Analysis (QIAGEN), using
a change in expression of ±25% and a false discovery rate
threshold ≤0.05 to select transcripts.
RT-qPCR
Total RNA was extracted as before and reverse transcribed
using MMLV Reverse Transcriptase (Promega) with ran-
dom hexamer primers (Promega) according to the manu-
facturer’s instructions. All RT-qPCRassays were performed
with exon-spanning TaqMan RNA expression assays (In-
vitrogen) using Universal Master Mix II (Invitrogen two)
on a 7900HT analyser (Applied Biosystems). Treated sam-
ples were normalized to controls with the Ct formula
using 18S rRNA as an endogenous control.
RNA immunoprecipitation (RIP)
Cells were collected by trypsinization and re-suspended
in RIP lysis buffer: 20 mM HEPES pH 7.4, 150 mM
KCl, 5 mMMgCl2, 0.5% NP40, 400U/ml RNase inhibitor
(Promega), 1 mM DTT, 400 M VRC (NEB), protein
(Roche) and phosphatase inhibitor (Calbiochem). Lysates
were stored at −80◦C overnight. RNA was immunoprecip-
itated with rabbit anti-LARP1 polyclonal antibody (SDIX-
Novus Biologicals) or rabbit IgG isotype control (Cell Sig-
nalling Technology) following the method described by
Keene et al. (26). RNAwas extractedwith Trizol (Life Tech-
nologies) and purified with the RNA clean-up and concen-
tration micro kit (Norgen Biotek). To generate cDNA, im-
munoprecipitated RNA was reverse transcribed using the
SensiScript R© RTKit (Qiagen) following the manufacturer’s
instructions. RT-qPCR was performed as described earlier.
The fold enrichment for each target was measured by com-
paring the Ct values of LARP1-immunoprecipitated frac-
tion to the IgG isotype fraction and normalized using the
Ct formula.
Protein extraction and western blotting
Cells were washed and incubated with protein lysis buffer
(1% NP-40, 10 mM Tris–HCl pH 7.5, 150 mM NaCl,
with protease and phosphatase inhibitors as before) for
10 min on ice. Lysates were cleared by centrifugation and
protein was quantified using the microBCA protein assay
kit (Thermo Scientific). Protein samples were boiled with
Laemmli buffer and separated by sodium dodecyl sulphate-
polyacrylamide gel electrophoresis (SDS-PAGE). Proteins
were transferred to nitrocellulose membranes. Blocking
and antibody incubation was performed according to anti-
bodymanufacturers’ instructions with anti-LARP1 (rabbit,
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SDIX-Novus Biologicals), anti-BCL2 (mouse, Santa Cruz),
anti-BIK (goat, Santa Cruz) and anti-HSP60 (rabbit, Ab-
cam) antibodies. Appropriate HRP-conjugated secondary
antibodies were obtained from Dako.
Transfection and transduction
Plasmids containing shGFP (TR30016) and shLARP1
(TF303581D) sequences, the Flag-BCL2 overexpression
plasmid and matched, empty vector control were all pur-
chased from Origene. Cells were transfected using Ef-
fectene (Qiagen), as per manufacturer’s instructions, and
selected with 2 g/ml puromycin after 48 h. (Sigma-
Aldrich). To create lentiviral-transduced lines, cells were
infected with virus and selected with 2 g/ml puromycin
after 24 h. Lentiviruses and Mission shRNA constructs
were obtained from Sigma-Aldrich (Control [SHC0016]
and shLARP1 [TRCN0000150984, TRCN0000152624,
TRCN0000152891]).
For transient knockdown, sub-confluent cells were
transfected using Dharmafect 1 (GE Dharmacon) as pre-
viously described (27), with control non-targeting siRNA
(GGUCCGGCUCCCCCAAAUG) or LARP1-targeting
siRNA (GAAUGGAGAUGAGGAUUGC, AGACU-
CAAGCCAGACAUCA) synthesized by Eurofins, or
BCL2-targeting siRNA (D-003307–02) obtained from GE
Dharmacon.
Luciferase UTR reporter assays
The 3′ UTR sequence for BCL2 and the 3′ and 5′ UTR se-
quences for BIK were obtained from the UCSC Genome
Browser (28). The sequence of the 203 bp BCL2-ARE re-
gion was as described by Ishimaru et al. (29). Sequences
were cloned into 3′ and 5′ UTR renilla luciferase reporter
constructs (SwitchGear Genomics). -actin 5′ UTR cloned
into a renilla luciferase reporter construct was used as a
negative control. Cells were co-transfected with a firefly
luciferase control plasmid using Effectene as before. Re-
nilla and firefly luciferase activity was analysed using the
Dual-luciferase reporter assay system (Promega) in tripli-
cate in 96-well plates with luminescence recorded using the
LUMOstar Optima plate reader (BMG Labtech). Renilla
luminescence was normalized to firefly activity and con-
trol, and LARP1 knockdown samples compared. For lu-
ciferase mRNA analysis, total RNA extraction, with on-
column DNAase-digestion and cDNA production was per-
formed as described above. Custom renilla and firefly lu-
ciferase mRNA TaqMan assays were obtained from Invit-
rogen Life Technologies.
LARP1 purification
Full length LARP1 (amino acids 1–1019) was cloned into
a modified pET28 vector that expressed an N-terminal
6×HIS-MBPLARP1 fusion protein. Protein was expressed
using autoinduction of BL21(DE3) cells for 3 h at 37◦C and
then 18◦C overnight. A total of 15 g of cells were lysed the
same day as harvesting using homogenization in lysis buffer
(50 mMTris pH 7.5, 500 mMNaCl, 30 mM imidazole, 10%
glycerol). Protein was purified using batch binding of 5 ml
of HisPur Ni-NTA Resin (ThermoScientific) and eluted in
lysis buffer with the addition of 250 mM imidazole. The N-
terminal 6×HIS-MBP tagwas cleaved overnight using TEV
cleavage and the protein was further purified from contam-
inants and nucleic acid using tandem anion and cation ex-
change and size exclusion chromatography.
Electrophoretic mobility shift assays (EMSAs)
RNA was transcribed in vitro at 37◦C for 14 h using T7
RNA polymerase and gel purified. RNAs were 5′ end la-
belled with [ -32P]ATP (Perkin Elmer) using T4 polynu-
cleotide kinase (NEB) and gel purified again. Each bind-
ing reaction contained the indicated final concentration of
recombinant LARP1, five hundred counts of radiolabelled
RNA (<2 nM final concentration), binding buffer (20 mM
Tris–HCl, pH 8, 150 mMNaCl, 10% glycerol, 1 mMDTT),
1 g bovine serum albumin (BSA) and 0.5 g tRNA. Reac-
tions were incubated on ice for 30 min and analysed on an
8% polyacrylamide (29:1) native 0.5× tris-glycine gel with a
5% stacking gel at 4◦C. Gels were dried, exposed overnight
to phosphor screens and scanned with a Fuji plate reader.
RNA sequences:
BIK construct 1:
UGACCACUGCCCUGGAGGUGGCGGCCUGCU
GCUGUUAUCUUUUUAACUGUUUUCUCAUGA
UGCCUUUUUAUAUUUAAACCCCGAGAUAGU
GCUGGAACACUGCUGAGGU;
BIK construct 2: GUGCUGGAACACUGCUGAGG
UUUUAUACUCAGGUUUUUUGUUUUUUUUUU
AUUCCAGUUUUCGUUUUUUCUAAAAGAUGA
AUUCCUAUGGCUCUGCAAUUGUCACCGGUU
AACUGUGGCCUGUGCCCAGGAAGAGCCAUU
CACUCC;
BIK construct 3: GGAAGAGCCAUUCACUCCUG
CCCCUGCCCACACGGCAGGUAGCAGGGGGAGU
GCUGGUCACACCCCUGUGUGAUAUGUGAUG
CCCUCGGCAAAGAAUCUACUGGAAUAGAUUCC
GAGGAGCAGGAGUGCUCAAUAAAAUGUUGG
UUUCCAGC.
BCL2 construct 1: GGCUCCACCUGGAUGUUCUG
UGCCUGUAAACAUAGAUUCGCUUUCCAUGU
UGUUGGCCGGAUCACCAUCUGAAGAGCAGACG
GAUGGAAAAAGGACCUGAUCAUUGGGGAAG
CUGGCUUUCUGGCUGCUGGAGGCUGGGGAG
AAGGUGUUCAUUCACUUGCAUUUCUUUGCC
CUGGG;
BCL2 construct 2: GCCCUCCUGCCCUCCUUCCG
CGGGGGCUUUCUCAUGGCUGUCCUUCAGGG
UCUUCCUGAAAUGCAGUGGUGCUUACGCUC
CACCAAGAAAGCAGGAAACCUGUGGUAUGA
AGCCAGACCUCCCCGG;
BCL2 construct 3: GCCUGUUUUGUCUUUUGU
UGUUGUUCAAACGGGAUUCACAGAGUAUUU
GAAAAAUGUAUAUAUAUUAAGAGGUCACGG
GGGCUAAUUGCUGGCUGGCUGCCUUUUGCU
GUGGGGUUUUGUU;
BCL2 construct 4: GCCCUCCAGAUAGCUCAUUU
CAUUAAGUUUUUCCCUCCAAGGUAGAAUUU
GCAAGAGUGACAGUGGAUUGCAUUUCUUUU
GGGGAAGCUUUCUUUUGGUGGUUUUGUUUA
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UUAUACCUUCUUAAGUUUUCAACCAAGGUU
UGCUUUUGUU.
OAZ1:
GGCCGCCUCGGGGCUGGGCAUCCGGCCCCU
GGGGCCACCCCUUGUCAGCCGGGUGGGUAG
GAACCGUAGACUCGCUCAUCUCGCCUGGGU
UUGUCCGCAUGUUG.
RPS6:
CCUCUUUUCCGUGGCGCCUCGGAGGCGUUC
AGCUGCUUCAAG.
BIK 5′ UTR:
GCAGACACGAAGCCUCCCGGGUGGCUUACA
GACGCUGCCAGCAUCGCCGCCGCCAGAGGAGA;
BIK CDS1:
GUCUGAAGUAAGACCCCUCUCCAGAGACAU
CUUGAUGGAGACCCUCCUGUAUGAGCAGCUCC
UGGAACCCCCGACCAUGGAGGUUCUUGGCA
UGACUGACUCUGAAGAGGACCUGGACCCUA
UGGAGGACUUCGAUUCUUUGGAAUGCAUGG
AGGGCAGUGACGCAUUGGCCCUGCGGCUGGC;
BIK CDS2:
GAGGACAUCAGGGAUGUUCUUAGAAGUUUC
AUGGACGGUUUCACCACACUUAAGGAGAACAU
AAUGAGGUUCUGGAGAUCCCCGAACCCCGG
GUCCUGGGUGUCCUGCGAACAGGUGCUGCU
GGCGCUGCUGCUGCUGCUGGCGCUGCUGCU
GCCGCUGCUCAGCGGGGGCCUGCACCUGCU
GCUC.
Competition assays
RPS6 (42mer) was annealed in 1× binding buffer at 95◦C
for 1 min and snap cooled. RPS6 was prebound to 250 nm
LARP1 for 30 min at 4◦C in binding buffer, 0.5 g TRNA
and 1 g BSA. Prebound LARP1 was competed off with
5× cold RNA stocks yielding a final concentration of 1, 10,
30 Mof RPS6, BCL2 or OAZ1. Reactions were incubated
on ice for 30 additional minutes and 8l was then loaded on
a 0.5× TBE gel, run for an hour at 120V, dried and exposed
overnight.
Immunofluorescence (IF) staining and confocal imaging
Cells (SKOV3) were cultured on glass coverslips for 24 h.
Cytoplasmic mRNP granule formation was triggered by
treatment with 5 g/ml sodium arsenite (Sigma-Aldrich)
for one hour. Cells were washed before being incubatedwith
PHEM fixative (4% PFA, 60 mM PIPEs, 25 mM HEPES,
10 mM EGTA, 4 mM MgCl2) for 10 min. Fixative was re-
moved and cells were washed and blocked in PBSTB buffer
(1% BSA, 0.1% TritonX-100) for 1 h. Cells were stained
with antibodies to DCP1A (Abnova), PABP (Abcam) and
LARP1 (SDIX- Novus Biologicals). Primary antibody so-
lution was applied and incubated overnight at 4◦C. Af-
ter washing, Alexa Fluor-conjugated secondary antibod-
ies (Life Technologies) were applied and incubated at room
temperature for 1 h. Cells were washed and mounted with
ProLong Gold mounting medium with DAPI (Life Tech-
nologies). Immunofluorescence staining was analysed using
Leica 500 confocal microscope and images processed with
Leica LAS AF lite software.
3-(4,5-Dimethlythiazol-2-YI)-2,5-Diphenyltetrazolium Bro-
mide (MTT) viability and caspase activity assays
For MTT labelling, cells were cultured at 37◦C in 96-well
plates with 100 l media and labelled with 20 l of MTT
(3 mg/ml, Sigma-Aldrich) for 1 h. Precipitate was solubi-
lized overnight with 10% SDS in 0.01M HCl. Absorbance
at 570 nm was recorded on an OPTImax microplate reader
(Molecular Devices). MTT assays were performed at the
timepoints specified in figure legends. Caspase 3/7 activity
was assessed using the CaspaseGlo-3/7 Assay (Promega).
Cells were cultured at 37◦C in white 96-well plates (Corn-
ing). CaspaseGlo reagent was added to each well and plates
left at room temperature for 1 h before reading on a LU-
MOstar Optima plate reader (BMG Labtech). Assays were
performed at 24 h, unless otherwise stated.
Xenograft experiments
All animal experiments were performed by licensed inves-
tigators in accordance with the United Kingdom Home
Office Guidance on the Operation of the Animal (Scien-
tific Procedures) Act 1986 and within the published guide-
lines for the welfare and use of animals in cancer research
(30). Female SCID-Beige or NOD-SCID IL2R-gammanull
(NSG) mice (aged 6–8 weeks; Charles River) were used.
SKOV3 cells (2 × 106 unless otherwise specified) were in-
jected subcutaneously into the flanks of mice (at least five
per cohort). For limiting dilution experiments, cells were
diluted 1:1 in phenol-free growth factor-reduced Matrigel
(BD Biosciences) prior to implantation. Tumour dimen-
sions were measured using electronic callipers and tumour
volumes calculated by the equation: volume = (/6) × a ×
b × c, where a, b and c represent three orthogonal axes of
the tumour. Tumours were classed as measurable when they
reached≥5mm in any axis. Experiments were terminated at
2 months, or before any mouse reached pre-set welfare lim-
its. Tumours were collected and immediately fixed in 10%
formalin for 48 h before paraffin embedding and section-
ing.
Clonogenic assays
Single-cell suspensions of cells were seeded in 10 cm plates,
with 1–5 × 103 cells per plate and incubated for 2 weeks.
Colonies formed were fixed in ice-cold methanol and
stained with 0.5% crystal violet. Plates were photographed
using a GE ImageQuant LAS 4000 and colonies were
counted with ImageJ.
Flow cytometry
For cell cycle analysis, cells were trypsinized and fixed in ice-
cold 75% ethanol overnight, before RNAdigestion (RNAse
A, 100 g/ml) and propidium iodide staining (25 g/ml,
both Sigma-Aldritch). Samples were analysed on a FAC-
SCalibur (BD Biosciences). Cell cycle distribution was de-
termined using FlowJo software (FlowJo LLC). For assess-
ment of apoptosis, cells were resuspended in Annexin V-
binding buffer (BioLegend) and incubated for 10 min with
Annexin V-FITC antibody (IQ Products). Cells were then
washed twice and, following addition of propidium iodide,
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analysed as before. Assessment of CD133 membrane posi-
tivity was performed usingCD133/1-APC and IgG isotype-
APC (both MACS) and the Aldefluor assay was performed
as per manufacturer’s instructions (Stemcell Technologies).
BCL2 promoter activity assay
ABCL2 promoter construct containing P1 and P2 elements
(ATG to −3934) upstream of firefly luciferase (31) was ob-
tained from Addgene (plasmid LB332). Transient LARP1
knockdown was performed as before. Effectene was used to
introduce the BCL2 promoter construct together with a re-
nilla luciferase control for data normalization. Twenty-four
hours after transfection, total RNA was collected and rela-
tive levels of firefly and renilla luciferase mRNAwere deter-
mined by RT-qPCR as described above.
Gene expression array data
Expression data for LARP1 was obtained from On-
comine (www.oncomine.org) for three independent datasets
(TCGA (32), Hendrix et al. (33), Bonome et al. (34)). Fold
change was calculated as median-centered intensity of each
cancer sample divided by the mean of non-cancer samples.
Significance was calculated using the Student t-test. Sur-
vival association was determined by Cox regression analysis
using the survival package of R. Progression-free survival
(PFS) data in ovarian cancer and overall survival data in
breast cancer were obtained from kmplot.com (35,36). Ar-
ray gene expression data for PROM1 in the NCI60 panel
was obtained from the CellMiner online tool (37).
Immunohistochemistry
A tissue microarray (TMA) containing normal ovarian tis-
sue (n = 40) and ovarian cancer cores (n = 40) was ob-
tained from US Biomax (OV801). Other TMAs were devel-
oped in Imperial College as detailed in Results. Paraffin was
removed with Histoclear and sections were rehydrated in
graded alcohols and heated in amicrowave oven at 900W for
15min in citrate buffer pH6. Tissue sectionswere pretreated
using 0.3% H2O2 in phosphate bufferedsaline (PBS), rinsed
in PBS and then incubated with 20 l/ml normal goat
serum. Primary antibodies, anti-LARP1 (SDIX-Novus Bi-
ologicals) or anti-Ki67 antibody (Leica) were diluted in PBS
and incubated overnight at 4◦C. Secondary or biotinylated-
secondary antibodies were incubated for 30 min at room
temperature and then processed with the Polymer-HRPKit
(BioGenex), or stained using the Vectastain Elite ABC Kit
(Vector labs) and ImmPACT DAB (Vector labs). Tissues
were then counterstained with haematoxylin. Intensity of
staining was defined for each specimen (0–3, with 3 being
most intense) multiplied by the percentage of cells stain-
positive (to give a total score out of 300). All images were
captured using a Nikon Eclipse ME600. Xenograft samples
were processed in the same manner as clinical TMAs.
LARP1 ELISA
Nunc MaxiSorp plates (Thermo Scientific) were coated
overnight at 4◦C with anti-LARP1 antibody (mouse, Ab-
nova). Plates were blocked with casein solution (Pierce)
then incubated with patient samples diluted 1:20 in AD3
assay diluent (Neuromics). Serial dilutions of recombinant
LARP1 protein (Abnova) formed the standard curve. Plates
were washed with PBST then incubated with anti-LARP1
antibody (rabbit, SDIX – Novus Biologicals) diluted in
PBST. Following a further wash in PBST, plates were in-
cubated with peroxidase-conjugated goat anti-rabbit sec-
ondary antibodies (Dako) diluted in PBST. Plates were
developed using Luminata Forte ELISA HRP substrate
(EMD Millipore) and read using a LUMOstar Optima
plate reader (BMG Labtech).
Statistical analysis
Statistics analyses were performed using GraphPad Prism
software (GraphPad Software Inc.), unless otherwise
stated. Statistical tests appropriate to the experiment were
chosen as indicated in figure legends (Student t-test, Chi-
Squared, Log-Rank). P ≤ 0.05 was taken to be statistically
significant.
Study approval
Tissue and plasma samples were provided by the Ovarian
Cancer Action Biobank, supported by Ovarian Cancer Ac-
tion and Imperial College Healthcare NHS Trust Tissue
Bank, supported by the National Institute for Health Re-
search (NIHR) Biomedical Research Centre and based at
Imperial College Healthcare NHS Trust and Imperial Col-
lege London. Informed consent was taken from all patients
prior to sampling. Study approval was obtained from the
local Research Ethics Committee.
RESULTS
Transcriptomic analysis on LARP1 knockdown identifies al-
terations in the expression of survival-related genes
In a previous systematic screen of LARP1 expression in di-
verse malignancies, we found that the protein was highly
expressed in several different cancer types, including EOC
(15). To explore the role of LARP1 in the ovarian cancer
cell, we performed mRNA-sequencing following LARP1
knockdown in the malignant ovarian OVCAR8 cell line.
Data from three biological replicates were combined. In
control cells, LARP1 was in the top 7% of the most abun-
dant mRNAs, with transcript abundance comparable to
translational components such as EIF4A3 and RPL36A,
and together with SSB, was the most highly expressed
LARP family member (Supplementary Figure S1A). Fol-
lowing LARP1 knockdown, an equal number of mRNAs
displayed increased and decreased abundance (Figure 1A).
Ingenuity gene ontology analysis revealed transcripts with
altered levels on LARP1 knockdown were significantly en-
riched for functions linked to cancer (Supplementary Fig-
ure S1B). Molecular and cellular function analysis showed
enrichment for genes associated with cell growth and prolif-
eration, and cell death and survival (Supplementary Figure
S1C).
In order to identify transcripts whose stability is po-
tentially regulated by LARP1, we cross-referenced our
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Figure 1. LARP1 knockdown causes alteration in the cancer cell transcriptome. (A) Frequency distribution of Log2-fold change in transcript abundance
in OVCAR8 cells following transient LARP1 knockdown (LARP1 knockdown relative to control). (B) Venn diagram showing the overlap between genes
with altered mRNA abundance on LARP1 knockdown, with the published LARP1–mRNA interactome, together with the P-value for the hypergeometric
probability of this overlap, calculated using the R dhyper function (based on 2086 differentially expressed mRNAs and an mRNA interactome with 6784
members) (15). Of the 758 genes present in both datasets molecular ontology enrichment with Ingenuity Pathway Analysis (IPA) was performed (-log[BH-
corrected P-value] shown, bold dashed line indicates P = 0.05). (C) RT-qPCR validation of fold changes in mRNA abundance of key survival-associated
genes identified from the IPA enrichment analysis following LARP1 knockdown. ***P < 0.001, **P < 0.01, *P < 0.05. Student t-test. Minimum of three
experimental repeats. Error bars indicate SEM.
RNA-seq data with the previously published LARP1–
mRNA interactome, derived from a LARP1 RNA-
immunoprecipitation and expression array analysis (RIP-
Chip) experiment performed in HeLa cells (15). Although
these data were obtained from a cell line derived from a
different gynecological malignancy, we hypothesized that
protein–mRNA interactions would be sufficiently con-
served to yield useful trends. Indeed, we found geneswith al-
tered expression after LARP1knockdown inOVCAR8 cells
were more likely to be represented in the LARP1–mRNA
interactome (hypergeometric probability distribution, P =
0.042), suggesting that interactions between LARP1 pro-
tein and target mRNAs could control their abundance (Fig-
ure 1B). Of the 758 genes both differentially expressed on
LARP1 knockdown and in complex with LARP1 protein,
49% showed decreased transcript abundance on LARP1
knockdown, whilst 51% showed increased abundance, sug-
gesting LARP1 may be capable of both stabilising and
destabilising transcripts. Functional enrichment analysis of
these 758 genes revealed that the regulation of cell survival
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was the most significant biological trait (Figure 1B). Fol-
lowing LARP1 knockdown, mRNA levels of pro-survival
genes such as BCL2, ERBB3 and AKT3 were significantly
reduced while expression of pro-apoptotic genes, includ-
ing BIK, TNF and DAPK2 were increased. To validate the
RNA-seq findings, we repeated LARP1 knockdown with
two independent siRNAs and confirmed changes in expres-
sion of these genes with RT-qPCR (Figure 1C).
These data demonstrate LARP1 knockdown has a
marked effect on the cancer cell transcriptome and alters
the expression of key apoptosis-related genes.
LARP1 is a component of BCL2 messenger ribonucleopro-
tein (mRNP) complexes and promotes BCL2 transcript sta-
bility
The positive and highly significant association between
LARP1 expression and B-cell lymphoma 2 (BCL2) mRNA
transcript abundance was of particular interest. BCL2 is an
important anti-apoptotic oncoprotein, known to promote
chemotherapy resistance in ovarian cancer cells and to be
associated with patient outcomes (38–41). By contrast, BIK
encodes a pro-apoptotic protein. To confirm LARP1 pro-
tein interacts with BCL2 and BIK mRNAs, as suggested
by the published LARP1 interactome (15), we performed
RNA-immunoprecipitation in OVCAR8 and SKOV3 ovar-
ian cancer cell lines (Figure 2A). OAZ1 and 18S were used
as controls for this and subsequent experiments as they are
absent from the LARP1-interactome (15). Both BCL2 and
BIK transcripts were highly enriched in anti-LARP1 im-
munoprecipitates when compared to the OAZ1 and 18S in
which no significant fold-enrichment was observed (Figure
2B). These data confirmed that BCL2 and BIK co-associate
with LARP1 in mRNP complexes.
As LARP1 has been identified as a regulator of mRNA-
stability (13–15), and BCL2 expression is known to be post-
transcriptionally regulated (29), we investigated whether
the changes in transcript abundance of BCL2 and BIK
following LARP1 knockdown were due to an effect on
their stability. To assess this, we knocked-down LARP1
and treated cells with actinomycin D to halt transcrip-
tion. LARP1 knockdown resulted in significantly increased
apoptosis, when compared to control cells, (Figure 2C and
D), supporting the importance of LARP1 in the post-
transcriptional regulation of cell survival. We assessed
mRNA abundance at 6 h and observed a significant de-
crease inBCL2 transcript levels in LARP1 knockdown cells
when compared to controls, demonstrating that LARP1 is
required to maintain the stability of BCL2 transcripts. The
opposite trendwas observed forBIK, where LARP1 knock-
down was associated with an increase in BIK mRNA sta-
bility (Figure 2E). The same trend was observed on west-
ern blotting (Figure 2F). In contrast, there was no signifi-
cant change in the transcript stability of MAPK14, a neg-
ative control. From this we concluded that LARP1 exerts
a binary effect on BCL2 and BIK, stabilising BCL2 whilst
destabilising BIK mRNAs, with the net effect of resisting
apoptosis.
LARP1 regulates target stability at the level of the 3′ UTR
The 3′-and 5′ untranslated regions (3′ UTRs) of mRNAs
contain regulatory elements that determine their stabil-
ity (42). We hypothesized that the effect of LARP1 on
BCL2 and BIK stability may be dependent on sequences
present in their UTRs. BIK transcripts have a 407 nt 3′
UTR, whilst the BCL2 3′ UTR is 5.2 knt long. We de-
signed reporter constructs with 3′ UTR sequences of both
genes downstream of the renilla luciferase gene (Figure
3A). OVCAR8 and SKOV3 cells were co-transfected with
a firefly luciferase plasmid to allow data normalization. In
both cell lines LARP1 knockdown resulted in a signifi-
cant increase in luciferase activity in the BIK 3′ UTR con-
struct when compared to the empty vector control, suggest-
ing LARP1 destabilizes BIK mRNA in 3′ UTR-dependent
manner (Figure 3B). We then created two equal-sized, over-
lapping constructs, spanning the length of the BCL2 3′
UTR (BCL2-UTR-A and BCL2-UTR-B). Addition of ei-
ther BCL2 3′ UTR sequence (A or B) resulted in a signifi-
cant decrease in luciferase signal on LARP1 knockdown,
with a greater effect on stability seen for the proximal 3′
UTR construct (BCL2-UTR-A). This stop codon-proximal
region contains a 203 nt sequence, termed the BCL2-ARE,
with multiple AU-rich elements (AREs), pentamer motifs
that are important in determining transcript stability (42).
This region has previously been implicated in the regulation
of BCL2mRNA stability (29). We created a third construct
containing only this 203 nt sequence (BCL2-ARE). Follow-
ing LARP1 knockdown, there was no significant change in
luciferase activity in this construct compared to the control
plasmid (Figure 3B), suggesting that the LARP1-mediated
stability effect is dependent on additional sequences outside
this well-characterized region. Similar trends were observed
when analysing luciferase transcript abundance with RT-
qPCR (Figure 3C), confirming changes were due, at least
in part, to effects on mRNA stability.
As recent work has suggested a role for LARP1 in reg-
ulating the translation and stability of TOP-bearing mR-
NAs via their 5′ UTRs (12,16,17), we investigated whether
LARP1 could mediate transcript stability via the 5′ UTR,
as well as the 3′ UTR of its target genes. We performed the
luciferase assay, as described above but using a 5′ luciferase
reporter system containing BIK 5′ UTR or the 5′ UTR of a
control (-actin) in OVCAR8 and SKOV3 cells. Following
LARP1 knockdown, there was no significant change in lu-
ciferase activity in the two constructs (Supplementary Fig-
ure S1D). In line with our previous findings (15), these data
suggest that LARP1 differentially regulates mRNA stabil-
ity through associations with the 3′ UTR of target mRNAs.
To identify potential sites of interaction between LARP1
and the 3′ UTR of target transcripts, we created approx-
imately equal length fragments of the entire BIK 3′ UTR
and four similar sized RNA constructs of the pyrimidine-
rich regions of the BCL2 3′ UTR, sequences with which the
DM15 has been shown to interact (12). We then analysed
binding by whole length LARP1 protein (Supplementary
Figure S2A and S2B). We observed an interaction between
LARP1 and all four pyrimidine-rich fragments of the BCL2
3′ UTR tested. LARP1 interacted with construct 3 with
∼4× higher affinity (Supplementary Figure S2B and Figure
 at Im
perial College London on M
ay 18, 2016
http://nar.oxfordjournals.org/
D
ow
nloaded from
 
1234 Nucleic Acids Research, 2016, Vol. 44, No. 3
Figure 2. LARP1 is a component of BCL2-containing mRNP complexes and promotes transcript stability. (A) Schematic of LARP1 RNA-
immunoprecipitation (RIP) with representative western blot of LARP1 protein following LARP1-immunoprecipiation in OVCAR8 and SKOV3 cells.
(B) RT-qPCR analysis of BCL2 and BIK mRNA obtained from RIP with anti-LARP1 and IgG control antibodies in OVCAR8 cells. OZA1 and 28S were
included as negative controls. (C) Representative cell images following LARP1 knockdown and 8 h exposure to actinomycin D (Scale bar 200 m). (D)
Following transient knockdown of LARP1, OVCAR8 cells were treated with actinomycin D to halt transcription and apoptosis (as determined by cleaved
Caspase 3/7) was monitored using the CaspaseGlo assay (data normalized to T = 0, at the time of actinomycin-D administration). **P < 0.01, *P <
0.05. (E) Stability of BIK and BCL2 mRNA following treatment with actinomycin D for 6 h. Relative abundance was determined by RT-qPCR (Ct).
MAPK14 was chosen as a negative control as its mRNA abundance did not alter on LARP1 knockdown in the RNA-seq dataset. Student t-test. Minimum
of three experimental repeats. Error bars indicate SEM. (F) Western blotting of BIK and BCL2 protein levels following LARP1 knockdown.
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Figure 3. LARP1 regulates stability at the level of the 3′ UTR and binds the BCL2 3′ UTR via its DM15 domain. (A) Schematics outlining construction
of 3′-untranslated region (3′ UTR) reporter constructs for BIK and BCL2. Both were compared relative to a control vector with no additional 3′ UTR
sequence. (B) OVCAR8 and SKOV3 cells were co-transfected with Renilla luciferase 3′ UTR constructs and a control Firefly luciferase control vector.
Renilla luciferase activity following LARP1 knockdown was determined for each 3′ UTR construct cells. Data was normalized to Firefly luciferase activity.
(C) OVCAR8 cells were co-transfectedwithRenilla luciferase 3′ UTRconstructs and a controlFirefly luciferase control vector andRenilla luciferasemRNA
abundance following LARP1 knockdown was determined using RT-qPCR. (D) Electrophoretic mobility shift assay (EMSA) of LARP1 with a fragment
of the BCL2 3′ UTR (construct 3). The affinity of this interaction is indicated. (E) Competition experiment analysed by EMSA of LARP1 pre-bound to
radiolabelled RNA representing the 5′ TOP of RPS6 and competed with cold competitors, as indicated. (F) Confocal immunofluorescence microscopy of
SKOV3 cells treated with sodium arsenite to trigger aggregation of mRNP bodies. Cells were stained for LARP1 protein (green) and either the P-body
marker DCP1a or stress granule marker PABP (both red). Scale bar 10 m (top) and 25 m (bottom).
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3D). The interactions between LARP1 and these constructs
was maintained by the DM15 region of LARP1 (data not
shown). We also tested the 3′ UTR of OAZ1, which is a se-
quence that was not identified in the LARP1 interactome
(15), two regions in the coding sequence of BIK and the 5′
UTR of BIK for binding to LARP1; none of these bound
with affinity tighter than 250 nM (Supplementary Figure
S2C).
To examine the specificity of these interactions, we con-
ducted competition assays using the 5′ UTR from RPS6,
which we have shown to bind the DM15 motif of LARP1
specifically (12). As judged by radiolabelled RPS6 that
was displaced by cold competitor RNA, these experiments
demonstrated that LARP1 specifically binds the BCL2 con-
struct 3, but not the negative control, the OAZ1 3′ UTR
(Figure 3E). Thus, the binding of LARP1 to BCL2 con-
structs 1, 2 and 4 and to the BIK constructs seems to be
non-specific. Since the LARP1 protein used in these experi-
ments was expressed and purified from Escherichia coli, it is
possible that post-translational modifications are required
to tune the binding of LARP1 to the BIK 3′ UTR.
LARP1 has previously been found in stress granules, sites
of mRNA storage and P-bodies, sites of RNA degradation
(14,43). As LARP1 appeared to be capable of both posi-
tively and negatively regulating transcript stability, we were
interested to see if LARP1 was localized to these sites of
RNA fate determination in ovarian cancer cells. After in-
ducing the aggregation of mRNP granules with sodium ar-
senite treatment, we found LARP1 to be present in both
P-bodies and stress granules (Figure 3F, see Supplementary
Figure S2D and E for untreated cells). Thus, LARP1 both
differentially regulates transcript stability and is present at
sites of mRNA fate determination.
LARP1 is required for cell survival and chemoresistance
We hypothesized that, as LARP1 acted as a post-
transcriptional regulator of the apoptosis players BCL2 and
BIK, modulation of LARP1 expression in ovarian cancer
cells would affect their survival. Indeed, transient LARP1
knockdown decreased cell viability (Figure 4A) and in-
creased apoptosis (Figure 4B and C; Supplementary Fig-
ure S3A and B), with no associated change in cell cycle
distribution (Figure 4D). Similar trends in cell death were
seen in response to hypoxia and nutrient starvation, with
LARP1 knockdown increasing apoptosis (Supplementary
Figure S3C–E). An important determinant of survival in
patients with ovarian cancer is the response of their tu-
mours to chemotherapy, with tumours that are able to evade
the pro-apoptotic effects of anti-cancer treatment progress-
ing or recurring more rapidly. As LARP1 knockdown re-
sulted in apoptosis, we investigated whether the protein
is required to maintain chemotherapy resistance. Ovarian
cancer-derived SKOV3 and OVCAR8 cells are both known
to be resistant to platinum-based therapies (44). LARP1
knockdown alone in these lines had minimal effects on cell
morphology. As they are resistant to platins, exposure to
cis-diamine diplatinum (cisplatin/CDDP) caused minimal
change to the microscopic appearance of these cells at 24
hours. However, when combined with LARP1 knockdown,
the cells became rounded and detached (Figure 4E). This
was associated with up to a 4-fold increase in apoptosis and
a significant drop in viability relative to controls (Figure 4F
and G and Supplementary Figure S4A–C).
We repeated the experiment with two other chemothera-
peutics commonly used to treat EOC, paclitaxel and gem-
citabine. With both agents, LARP1 knockdown also led
to increased apoptosis and decreased viability compared
to drug treatment alone (Supplementary Figure S4D and
E). To further evaluate the platinum effect, we obtained
isogenic cell lines derived from the same patient before
and after the development of platinum resistance (PEO1
and PEO4, respectively). Resistant PEO4 cells have a plat-
inum IC50 five times that of their sensitive counterpart
(45). Higher LARP1 expression was seen in the platinum-
resistant cell line (SupplementaryFigure S4F), while knock-
down of LARP1 in both lines resulted in greater apopto-
sis after exposure to cisplatin (Supplementary Figure S4G).
These results indicate that LARP1 contributes to apoptosis
evasion in ovarian cancer cells andmaintains chemotherapy
resistance.
LARP1 is required for tumorigenicity and clonogenicity
To determine whether LARP1-mediated regulation of can-
cer cell survival was important for ovarian tumour develop-
ment, we induced stable knockdown of LARP1 (shLARP1)
in SKOV3 cells (Figure 5A, inset) and implanted them into
SCID-beigemice. Control cells (shGFP) developedmeasur-
able tumours with shorter latency compared to shLARP1
cells (median time 22 versus 36 days, P = 0.022; Supple-
mentary Figure S5A). Control xenografts also reached sig-
nificantly larger tumour size (Figure 5A and B). To ascer-
tain whether these differences were due to decreased pro-
liferation in shLARP1 cells, we analysed nuclear positivity
of the proliferation marker Ki67 with immunohistochemi-
cal (IHC) staining of fixed tumours. As expected, we found
no significant difference in proliferation between tumours
from each cohort (Figure 5C), suggesting that the effect of
LARP1 depletion on cell survival attenuates the tumour-
initiating potential of cancer cells. To model this in vitro,
we carried out clonogenic assays following LARP1 knock-
down. We found a significant decrease in colonies formed
fromovarian SKOV3 andOVCAR8 cells, and cervical squa-
mous cell carcinoma-derived HeLa cells (Supplementary
Figure S5B).
To further investigate whether LARP1 knockdown af-
fected the tumour initiating potential of ovarian cancer
cells in vivo, we performed a limiting dilution assay, in-
jecting decreasing numbers of SKOV3 cells with stable
non-targeting (lenti-shControl) or LARP1-targeting (lenti-
shLARP1) short-hairpin expression subcutaneously into
NOD-SCID IL2R-gammanull (NSG) mice (Figure 5D).
When 106 cells were injected, all mice developed bilateral tu-
mours, though the median latency was considerably greater
for tumours with LARP1 knockdown compared to con-
trols (19 versus 11 days, respectively; P = 0.011; Figure 5E
and F). At 105 cells per injection, measurable tumours were
not detected in 2/6 LARP1 knockdown injection sites. Tu-
mour latency was more pronounced, with a median time
to tumour development of 22 days in control cells, and 42
days in cells with LARP1-silencing (P< 0.001). At 8 weeks
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Figure 4. LARP1 knockdown increases basal apoptosis and chemosensitivity. (A) Cell viability following transient LARP1 knockdown in OVCAR8 and
SKOV3 cells determined by MTT assays. ***P < 0.001, **P < 0.01, *P < 0.05. (B) Relative levels of cleaved Caspase 3/7 determined by the CaspaseGlo
assay in OVCAR8 and SKOV3 cells 24 h after transient LARP1 knockdown. (C) Western blot analysis of cleaved PARP in OVCAR3 cells transduced
with lentiviral shLARP1 constructs. (D) Cell cycle distribution determined by propidium iodide staining following transient LARP1 knockdown. (E)
Schematic of cell transfection and cisplatin (CDDP) treatment with representative OVCAR8 cell images in each condition (Scale bar 200 m). (F) Percent-
age of Annexin V-positive cells following transient LARP1 knockdown and treatment for 24 h with 25 M cisplatin in platinum-resistant OVCAR8 cells
with representative dual-colour flow cytometry plots. (G) Normalized cell viability determined by MTT-based assay in OVCAR8 cells following LARP1
knockdown and treatment with 25 M cisplatin. ***P < 0.001, **P < 0.01, *P < 0.05. Student t-test. Minimum of three experimental repeats. Error bars
indicate SEM.
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Figure 5. Oncogenic effects of LARP1 in vivo. (A) SKOV3 control (shGFP) and LARP1 knockdown (shLARP1) cells were injected subcutaneously in
SCID-beige mice and tumour volume monitored over time (inset, western blot of LARP1 knockdown in implanted cells). (B) Final tumour weights at
sacrifice. (C) Ki67 percentage nuclear positivity of fixed and embedded xenograft tumours analysed by immunohistochemistry and representative examples
xenograft tumours stained with anti-Ki67 antibody (scale bar 100 m). (D) Western blot of LARP1 knockdown in SKOV3 stable cell lines using lentiviral
transduction, with schematic of cell injection protocol and representative tumours (scale bar 1 cm). (E) Limiting dilution assay results from SKOV3 cells
injected subcutaneously into NSG mice. (F) Kaplan-Meier curves of tumour-free survival for mice receiving 1 × 106 cells (n = 5) and 1 × 105 cells (n =
6). Log-rank test. (G) Final tumour volumes for mice receiving 1 × 106 cells and 1 × 105 cells, respectively. ***P < 0.001, **P < 0.01, *P < 0.05. Student
t-test. Error bars indicate SEM.
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following implantation of 104 cells, 2/6 tumours had de-
veloped in the control cohort, with no tumours found at
sites of shLARP1 cell implantation. No tumours were de-
tected when 103 shControl or shLARP1 cells were injected
in either dose cohort (Figure 5E) and tumors took longer
to develop in shLARP1 mice compared with controls (Fig-
ure 5F). As before, there was a striking difference in tumour
volumes between control and LARP1-knockdown tumours
(Figure 5G). These data indicate that LARP1 is required for
ovarian tumour initiation and progression.
LARP1 maintains CSC-like populations
Enhanced tumorigenicity, clonogenicity and chemotherapy
resistance are features often ascribed to cell populations
with cancer stem cell (CSC)-like properties (46). Given
LARP1 appears to regulate these traits, we hypothesized
that the protein may be important in maintaining CSC-like
populations. One of the best-characterizedmarkers of CSC-
like populations in a range of solid malignancies, including
EOC, is CD133 (47). We used the NCI60 panel expression
array dataset (37) to identify cell lines with PROM1/CD133
mRNA expression. We found a strong correlation between
publishedmRNA levels and flow cytometry-derivedCD133
membrane positivity (Supplementary Figure S6A). Knock-
down of LARP1 in OVCAR3 and IGROV-1 lines, and
in cervical cancer-derived HeLa cells, resulted in a signifi-
cant decrease in CD133+ cell populations (Figure 6A and
B; Supplementary Figure S6B). Having demonstrated that
LARP1 targets CSC-like cells, we compared its effects to
a positive control, salinomycin, identified as a selective in-
hibitor of breast cancer stem cell-like populations (48). As
expected, salinomycin reduced CD133+ populations in OV-
CAR3 cells, with the highest dose producing an effect equiv-
alent to LARP1 knockdown (Figure 6C).
No single marker has been shown to fully describe intra-
tumoral heterogeneity. We assessed the effect of LARP1
knockdown on aldehyde dehydrogenase (ALDH) activity,
another commonly used CSC marker. LARP1 knockdown
resulted in a decrease in ALDH activity (Figure 6D and E).
High expression of several key embryonic stem cell-related
transcription factors have been associated with enhanced
CSC-like traits, including SOX2, OCT4 and NANOG (49).
Following LARP1 knockdown, we found reduction in ex-
pression of all three genes, with the most pronounced effect
on NANOG (Figure 6F). These results show that LARP1
promotes several characteristics associated with CSC-like
cells, namely clonogenicity, tumorigencitiy, chemotherapy
resistance, expression of stem cell-associated genes and
maintenance of CSC marker-positive populations.
LARP1 enhances cell survival by promoting BCL2 expression
Our data demonstrate that BCL2 is an important promoter
of chemotherapy resistance and appears to be required for
CSC survival (39,40). We next investigated the effect of
LARP1 knockdown onBCL2 promoter activity.No change
was observed following LARP1 knockdown (Figure 7A),
confirming that the altered BCL2 transcript abundance ex-
pression seen on reduced LARP1 expression (Figure 1C)
and resultant change in BCL2 protein levels (Figure 7B)
were due to alterations in mRNA stability alone. To deter-
mine if the changes in BCL2 expression on LARP1 knock-
downwere sufficient to explain the observed phenotypes, we
used BCL2-targeting siRNA to reduce expression (Figure
7C). As expected, decreased expression of BCL2 resulted
in increased apoptosis in response to platinum treatment
(Figure 7D), and also reductions in CD133+ CSC-like pop-
ulations (Figure 7E). We next assessed the ability of BCL2
overexpression to rescue the effects of LARP1depletion. In-
deed, following knockdown of LARP1 and treatment with
cisplatin, transfection with a FLAG-tagged BCL2 overex-
pression construct resulted in a significant decrease in apop-
tosis when compared to control plasmid-transfected cells
(Figure 7F). These data indicate LARP1 promotes BCL2
mRNA stability and protein expression, without which ef-
fect cells demonstrate increased apoptosis and decreased
chemotherapy resistance.
LARP1 is highly expressed in ovarian cancer and predicts
prognosis
Having demonstrated LARP1 promotes ovarian cancer cell
survival, we investigated LARP1 expression in ovarian ma-
lignancies. First, we extracted data from three independent
expression array studies representing 735 patient samples
(32–34). LARP1 mRNA levels were significantly upregu-
lated in serous EOC, the most common epithelial subtype
(50), compared to non-malignant ovarian tissue in all three
studies (Supplementary Figure S7A). Similar trends were
observed comparing LARP1 mRNA expression in serous
EOC to normal ovarian surface, and fallopian tube, epithe-
lium (51,52) (P = 0.0072 and 0.022 respectively; Supple-
mentary Figure S7B and C). Using IHC analysis of ovarian
TMAs, we found significantly higher expression of LARP1
protein in ovarian cancer samples compared to normal
ovarian tissue (P < 0.001; Figure 8A and B). Similar re-
sults were obtained comparing serous ovarian cancers with
benign ovarian tumours (P = 0.021; Supplementary Fig-
ure S7D), and benign and malignant mucinous ovarian tu-
mours, rarer histological EOC subtypes (P= 0.033; Supple-
mentary Figure S7E).
Analysis of overall survival, using matched mRNA ex-
pression and patient outcome data obtained from The Can-
cer Genome Atlas (TCGA) project (32), revealed that pa-
tients with the highest LARP1 expression had significantly
worse outcomes, with a 29% increased risk of death at any
time (n = 566, HR 1.29, 95% CI 1.01–1.65, P = 0.042). We
then assessed the effect of LARP1 expression on PFS in
ovarian cancer. In an analysis of 1171 patient samples, those
with low LARP1 expression had significantly better PFS
than those with high LARP1 expression (HR 1.31, 95% CI
1.10–1.54, P = 0.0018; Supplementary Figure S7F). Inter-
estingly, this finding was not limited to ovarian cancer; by
analysing overall survival in 1115 breast cancer patients, we
found that high LARP1 expression was also predictive of
poor outcome (HR = 1.53, P < 0.001, 95% CI 1.2–1.96;
Supplementary Figure S7G), suggesting an oncogenic role
for LARP1 in other tumour types.
In an analysis of a TMA of 67 ovarian cancer cases col-
lected at initial debulking surgery, we showed that only
LARP1 expression and cancer stage were significant in-
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Figure 6. LARP1 is required for the maintenance of populations positive for putative cancer stem cell markers. (A) Representative histogram plot of
CD133+ OVCAR3 cells determined by flow cytometry (a line with <10% CD133-positivity) following LARP1 knockdown. (B) Mean CD133+ popula-
tions determined by flow cytometry following LARP1 knockdown in OVCAR3, IGROV1 and HeLa (cervical carcinoma-derived) cells. (C) Percentage
of CD133+ OVCAR3 cells following treatment with the anti-CSC agent salinomycin. (D) Representative flow cytometry plots of ALDEFLUORbright
OVCAR3 cells, with high aldehyde dehydrogenase activity, following LARP1 knockdown, determined using the Aldefluor assay. (E) Percentage of
ALDEFLUORbright OVCAR3 cells following LARP1 knockdown determined using the Aldefluor assay. (F) Relative mRNA expression of key stem
cell-associated transcription factors following LARP1 knockdown (Ct). ***P < 0.001, **P < 0.01, *P < 0.05. Student t-test. Minimum of three
experimental repeats. Error bars indicate SEM.
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Figure 7. BCL2 can rescue the LARP1 apoptotic phenotype. (A) BCL2 promoter activity following LARP1 knockdown (firefly luciferase mRNA normal-
ized to renilla luciferasemRNA control). (B)Western blot analysis of BCL2 protein levels following LARP1 knockdown. (C)Western blot analysis of BCL2
protein levels following BCL2 knockdown. (D) Percentage of Annexin V-positive OVCAR8 cells, determined by flow cytometry, following transient BCL2
knockdown, with and without co-treatment with cisplatin (25 M). (E) Percentage of CD133-posititve OVCAR3 cells, determined by flow cytometry, fol-
lowing transient knockdown of BCL2. (F) Percentage of Annexin V-positive OVCAR8 cells, determined by flow cytometry, following LARP1 knockdown
or transfection with control siRNA and treatment with cisplatin (25M), with co-transfection of a Flag-tagged control (F-empty) or BCL2-overexpression
(F-BCL2) construct. Minimum of three experimental repeats. Student t-test. Error bars indicate SEM.
dependent predictors of poor overall survival in patients
with ovarian malignancy (LARP1 HR = 1.13, 95% CI
1.01–1.27, P = 0.036; Figure 8C). To study this survival
effect in greater depth we obtained patient samples col-
lected as part of Trans-SCOTROC, a translational sub-
study within SCOTROC IV (53). This was a multi-centre,
randomized trial of flat-dosed (AUC 6) versus intrapatient
dose-escalated (median of AUC 7.2) single-agent carbo-
platin as first-line chemotherapy in 964 women with stage
IC-IV epithelial ovarian, fallopian tube or serous peritoneal
cancer. It was conducted between 2004 and 2009, before fu-
tility analysis confirmed a lack of superiority of the intra-
patient dose-escalated arm. A TMA was created using tu-
mour samples collected from 281 participants at primary
debulking surgery. This was stained using anti-LARP1 an-
tibody and scored blind by two independent histopatholo-
gists (inter-rater kappa coefficient of 0.7) with LARP1 levels
scored as ‘low’ or ‘high’. LARP1 expression was low in 139
patients and high in 142. When patients were stratified ac-
cording to LARP1 expression, those with high LARP1 ex-
pression had a significantly worse PFS (median 11.0 versus
16.5 months, P = 0.019) and overall survival (27.4 versus
48.5 months, P = 0.028) (Figure 8D).
To determine whether LARP1 could be regulating the
stability of BCL2 and BIK transcripts in patient tumours,
we evaluated trends in LARP1, BCL2 and BIK transcript
abundance in the TCGA ovarian cancer dataset. As ex-
pected, LARP1 and BCL2 mRNA levels showed a signif-
icant positive correlation, while LARP1 and BIK expres-
sion were negatively correlated (Figure 9A and B). Together
with our in vitro and in vivo data, this suggests a model
whereby LARP1 differentially regulates the mRNA stabil-
ity of pro- and anti-apoptotic transcripts in malignant ovar-
ian tumours to promote cell survival (Figure 9C).
As LARP1 is highly expressed in ovarian tumours, we hy-
pothesized that patients with underlying malignancy may
have higher levels of circulating protein. To investigate this
we developed a sandwich enzyme-linked immunosorbent
assay (ELISA) to accurately quantify LARP1 protein in
human plasma (Figure 10A and B). We found significantly
higher levels of circulating LARP1 protein in plasma from
women with underlying ovarian malignancy, than healthy
controls (Figure 10C). Analysing a subset of patients for
which there were paired plasma samples taken before and
after first-line surgical debulking, we found all patients ex-
hibited a drop in circulating LARP1 protein (Figure 10D).
 at Im
perial College London on M
ay 18, 2016
http://nar.oxfordjournals.org/
D
ow
nloaded from
 
1242 Nucleic Acids Research, 2016, Vol. 44, No. 3
Figure 8. LARP1 is highly expressed in ovarian cancers and predicts poor prognosis. (A) Representative TMA cores of normal ovarian tissue and EOC
samples, stained with anti-LARP1 antibody (scale bar 250 m). (B) LARP1 immunohistochemical scoring in healthy ovaries and ovarian cancers. (C)
Multivariate cox-regression analysis of overall survival in 67 cases of ovarian cancer. Hazard ratios for LARP1 score, as determined by IHC analysis of
sectioned tumours, given for a 10-point change in score. (D) A TMA of pre-treatment ovarian tumour tissue from 281 participants in the SCOTROC4
study was stained with anti-LARP1 antibody, and scored independently. Kaplan-Meier analysis of progression-free survival (PFS) and overall survival
(OS) is shown, with patients stratified by LARP1 score (Median PFS 16.5 versus 11.0 months and OS 48.5 versus 27.4 months in LARP1 low and high
tumours, respectively).
Though larger studies are required, these data suggest po-
tential as a circulating, as well as intratumoral, biomarker.
DISCUSSION
LARP1 promotes both the stabilization (13,15) and desta-
bilization (14) of selected messenger RNA transcripts. A
similar role has been ascribed to other LARPs including
LARP4b (54), suggesting a conserved function within the
LARP family. Here, we investigated the mRNA stability-
regulating role of LARP1 in EOC. We utilized tran-
scriptomic analysis following LARP1 knockdown, cross-
referenced against the LARP1mRNA interactome, to iden-
tify potential LARP1mRNA targets.We demonstrated that
genes with altered transcriptomic abundance on knock-
down were more likely to be represented in the interactome.
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Figure 9. LARP1 expression in ovarian tumors correlates with BIK and BCL2 expression. (A) Correlation of mRNA expression (Log2RPKM) in ovarian
tumors (n= 412) between LARP1 and BCL2 or BIK (Pearson R). Data from TCGAOvarian RNAseq cohort (tcga-data.nci.nih.gov). (B) Comparison of
upper and lower quartiles of LARP1 expression (Log2RPKM, n= 103 in each), by BCL2 or BIK expression (Wilcoxon test). Data as before. (C) A summary
of the role of LARP1 in the ovarian cancer cell. As a component of mRNP complexes containing transcripts of survival-associated genes, LARP1 acts to
simultaneously stabilize anti-apoptotic mRNAs, whilst destabilizing pro-apoptotic transcripts. The net effect is to promote apoptosis evasion, enhancing
tumorigenicity, chemoresistance and cancer stem cell (CSC)-like traits.
These transcripts were enriched for functions linked to cell
death and survival, and included BIK and BCL2. Previ-
ous studies of LARP1a in Arabidopsis suggest that LARP1
may have a net stabilizing effect on its target transcripts
(14). However, we found that an equal proportion of mR-
NAs showed increased and decreased abundance follow-
ing LARP1 knockdown. We also found that LARP1 can
simultaneously differentially regulate transcript fate, stabi-
lizing transcripts of the anti-apoptotic gene BCL2, whilst
destabilizing pro-apoptotic BIK mRNAs. Although repre-
senting opposing effects on RNA stability, the anticipated
net consequence of increased LARP1 is to enhance cancer
cell survival (Figure 9C). Indeed, we found that LARP1 is
required for apoptosis evasion and to ensure cell survival
following exposure to chemotherapy in platinum-resistant
ovarian cancer cells. Laboratory culture conditions provide
cells with a permissive environment for optimal growth,
whilst implantation into host animals presents potential ad-
ditional apoptotic triggers, such as decreased oxygen and
nutrient availability. As well as increased apoptosis under
hypoxic and nutrient-depleted conditions, LARP1 knock-
down in vivo was associated with attenuated clonogenicity
and tumorigenicity. We established that LARP1 exerts this
pro-survival effect, at least in part, by post-transcriptionally
promoting the expression of BCL2, a well-characterized
oncogenic anti-apoptotic protein and a promoter of cancer
cell survival (55). Upregulation of BCL2 is a negative prog-
nostic factor in ovarian cancer (56) and induces platinum re-
sistance (39). In ovarian cancer cells, we showed that knock-
down of BCL2 causes apoptosis and enhanced chemosensi-
tivity, while overexpression of BCL2 partially rescues the ef-
fects of LARP1 depletion. On LARP1 knockdown, we also
observed increased mRNA levels of pro-apoptotic genes,
such as BIK and DAPK2, and reduced expression of anti-
apoptotic genes, including ERBB3 and AKT3. Given these
changes, the apoptosis observed following LARP1 knock-
down is likely due to alterations in expression of multiple
LARP1 targets.
Using mouse models of ovarian malignancy, it has been
proposed that transformed stem cells may be the origin of
at least some types of EOC (22). Flow cytometry markers,
such as CD133 membrane expression and aldehyde dehy-
drogenase activity, can identify sub-populations of ovarian
cancer cells demonstrating CSC-like characteristics (47). As
well as a role in regulating key CSC-associated traits such as
clonogencity, tumour-initiating capability and chemother-
apy resistance, LARP1 is required to maintain CD133+
and Aldefluorbright putative CSC-like populations. LARP1
knockdown also leads to reduced expression of stem cell-
related transcription factors. Interestingly, LARP1 was one
of the most strongly downregulated genes in non-CSC-like
CD133− populations (57) in a study investigating global dif-
ferences in gene expression between CD133+ and CD133−
cells derived from a patient with progressive glioblastoma
multiforme. LARP1 has also been shown to bind mRNA in
embryonic stem cells, and expression of LARP1 falls dur-
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Figure 10. LARP1 protein is detectable in patient blood plasma. (A) A schematic of the LARP1 sandwich enzyme-linked immunosorbent assay (ELISA).
(B) The LARP1 ELISA standard curve. (C) Plasma LARP1 concentration in healthy female controls and patients with primary ovarian malignancies
sampled prior to primary surgery. (D) Plasma LARP1 concentration for 19 patients with underlying ovarian malignancy sampled before and after primary
surgery. Students t-test. Error bars indicate SEM.
ing cell differentiation (58). This suggests LARP1 may be
an important factor in the maintenance of stem cell-like
traits. Expression of BCL2 is elevated in CSC-like popula-
tions and targeted BCL2 inhibitors selectively kill leukemic
cancer stem cell populations (40). In ovarian cancer cells,
we showed that knockdown of BCL2 also reduces CSC-
like populations, suggesting that the LARP1-mediated anti-
CSC phenotypemay also bemediated via BCL2 expression.
Post-transcriptional regulation of mRNA expression is
coordinated by elements within the 5′ UTR of transcripts
that can affect translation efficiency, and 3′ UTR cis-acting
features that determinemessage stability (42). LARP1 inter-
acts with poly(A)-binding protein (PABP) (27) and has been
previously been identified as part of a 3′ UTR-associated
mRNP complex (13). We show here that the 3′ UTR is crit-
ical to the stability-regulating function of LARP1 and, in
the case of BCL2, the DM15 region of LARP1 is the site
with which it binds the 3′ UTR of its target mRNA. One
of the best characterized 3′ UTR stability-determining fea-
tures are AU-rich elements (AREs), recognized by RBPs
that induce degradation, whilst proteins that compete for
this interaction can promote stability (42). BCL2 has a
well-characterized ARE-rich region (BCL2-ARE) that de-
termines its mRNA stability (29); however the LARP1
stability-regulating effect acts independently of this region.
Here, we report for the first time that LARP1 expres-
sion is upregulated in ovarianmalignancies, with high intra-
tumoral levels associated with adverse prognosis. LARP1
has previously been identified as a predictor of poor prog-
nosis in hepatocellular (18) and lung (15) cancers, indicat-
ing it may be important in driving malignant progression
across multiple tumour types. Supporting a clinically mean-
ingful role for LARP1 in the post-transcriptional regulation
of BCL2 and possibly also BIK expression in ovarian ma-
lignancies, expression of LARP1 positively correlates with
BCL2, but is negatively correlated with BIK expression in a
study of over 400 ovarian tumours. Like LARP1, the RBP
HuR has previously been shown to have a dual effect on
mRNA stability, stabilizing oncogenic transcripts such as
VEGF (59), whilst destabilizing transcripts encoding the tu-
mour suppressor p16INK4 (60). Similarly, HuR has also
been associated with chemotherapy resistance (61), suggest-
ing differential regulation of stability by oncogenic RBPs is
not an uncommon event.
There is increasing evidence linking the LARP protein
family to cancer (11). By differentially regulating the stabil-
ity of pro- and anti-apoptotic mRNA transcripts, LARP1
acts as a post-transcriptional promoter of apoptosis eva-
sion in ovarian cancer cells. Our discovery of a corre-
lation between circulating levels of LARP1 and tumour
burden in ovarian cancer patients suggests that plasma
LARP1 levels could prove a useful non-invasive means of
measuring tumour LARP1 expression, which we intend
to prospectively validate. Our study suggests that, through
its post-transcriptional control of chemosensitivity, LARP1
is a potential future therapeutic target for the reversal of
chemotherapy-resistant disease and may have utility as an
accompanying biomarker.
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